• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Vireo Growth (CNSX:VREO) Stock Rallies On Scale While Margins Slip

    Simply Wall St·08/12/2026 02:48:35
    Listen to the news

    Vireo Growth stock came into today trading at CA$15.40 after a strong 7 day run and a solid 30 day gain, yet the real story sits inside the earnings release. The company reported revenue of US$209.3m this quarter and a net loss of roughly US$0.1m. That combination of rapid top line scale with an almost breakeven bottom line may matter more to long term holders than the latest price swing.

    Is Vireo Growth trading at a genuine discount, or is it simply reflecting its history of rising losses and dilution risk? See how its DCF value and P/S multiple compare on our valuation analysis for Vireo Growth

    Q2 2026 Earnings Summary

    • Revenue, Q2 2026 vs. Q2 2025: US$209.3m vs. US$48.1m (very large increase, roughly 4x year on year)
    • Net Loss, Q2 2026 vs. Q2 2025: US$0.1m loss vs. US$14.9m loss (loss narrowed sharply)
    • Basic EPS, Q2 2026 vs. Q2 2025: US$0.00 loss per share vs. US$0.80 loss per share (per share loss reduced meaningfully)
    • Adjusted EBITDA Margin, Q2 2026 vs. Q2 2025: 19.8% vs. 27.7% (margin declined, even as absolute adjusted EBITDA improved)

    Prefer clear visual charts instead of another wall of numbers and earnings tables? View a complete picture of Vireo Growth, with a focus on its valuation in an easy-to-scan dashboard, in the company report for Vireo Growth.

    CNSX:VREO Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    CNSX:VREO Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Vireo Growth earnings give bulls real scale

    For investors leaning bullish on Vireo Growth, the latest quarter backs the idea that this is becoming a much larger operator rather than just a rebrand story. Reported revenue reached US$209.3m and pro forma revenue implies a run rate above US$1b, with cannabis and agribusiness both contributing. Adjusted EBITDA of about US$41.5m and an almost breakeven net result indicate the model is now generating meaningful operating profit, even if the margin sits at 19.8%. A cash balance of US$122.7m supports the multi state growth agenda.

    Margins and M&A keep the bear case alive

    Bears focused on execution risk still have arguments to point to. Adjusted EBITDA margin fell to 19.8%, held back by lower margin non cannabis activities and recently acquired assets. Gross margin pressure outside core cannabis shows the agribusiness strategy comes with some trade off. The pipeline of pending deals and new states adds more complexity and integration risk, even with a relatively conservative balance sheet and a new asset based lending facility. Recent share price gains over 7 and 30 days also suggest expectations have moved up, which raises the bar for future quarters.

    Review whether Vireo Growth’s margin pressures and cash runway are isolated issues or early red flags. Scan our full risk analysis for Vireo Growth which shows 2 important warning signs.

    Stay Ahead With Vireo Growth

    If Vireo Growth’s rapid revenue scale and near breakeven result have caught your attention, register for free with Simply Wall St and add it to a Watchlist to track share price moves against fair value estimates and watch for a more attractive entry point. After you decide to take a position, use the Portfolio Command Center to cut through noise and keep on top of key developments that matter for your holdings. For a longer term view, tap into crowd wisdom and sentiment through the Community to see how other investors are thinking about the same risks and catalysts. This combination helps surface potential triggers and warning signs early so you can stay ahead of the market instead of reacting to it late.

    Curious About Alternative Stock Opportunities

    Fresh ideas often move first. While attention sits on Vireo Growth, other stocks can be building momentum under the radar for now. Do your homework before the crowd and act now.

    • Spot companies with steady balance sheets before they hit the spotlight by reviewing our curated list of solid balance sheet and fundamentals stocks (12 results) and see which names currently combine resilience with fundamentals that still look underappreciated.
    • Chase potential income workhorses while yields remain elevated by scanning the hand picked 4 dividend fortresses so you can judge which payouts might justify a place in your portfolio.
    • Track early movers in quantum computing as the theme gains attention by working through the pre filtered 26 quantum computing stocks and flagging any stocks that deserve deeper fundamental research.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.